Trials / Unknown
UnknownNCT04457856
A Study of TJ003234 in Rheumatoid Arthritis Patients
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Ascending Doses of TJ003234 in Rheumatoid Arthritis Patients
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 63 (estimated)
- Sponsor
- I-Mab Biopharma US Limited · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Study Purpose and Design: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Ascending Doses of TJ003234 in Rheumatoid Arthritis Patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TJ003234 injection | Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks) |
Timeline
- Start date
- 2020-08-06
- Primary completion
- 2023-03-01
- Completion
- 2023-03-01
- First posted
- 2020-07-07
- Last updated
- 2022-08-03
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04457856. Inclusion in this directory is not an endorsement.